Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus ...

Investing.com -- Atara Biotherapeutics Inc (NASDAQ: ATRA) stock surged 7% after the U.S. Food and Drug Administration (FDA) accepted the filing of its Biologics License Application (BLA) for ...

Atara Biotherapeutics Inc (NASDAQ:ATRA) saw its stock jump 7% following the U.S. Food and Drug Administration’s acceptance of ...

Bihar voter list revision nears its deadline with 7 lakh forms missing. 61 lakh million names face removal. Opposition ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

The Baloch Liberation Army has claimed responsibility for a bomb blast in Quetta that killed Major Anwar Kakar, a senior ...

Ever since we have won war against India, Pakistan is continuously receiving admiration and appreciation from the world, ...

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...